Moderna, Inc. $MRNA Position Reduced by Swedbank AB

Swedbank AB decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 79.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,802 shares of the company’s stock after selling 74,883 shares during the period. Swedbank AB’s holdings in Moderna were worth $561,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in MRNA. Voloridge Investment Management LLC increased its stake in Moderna by 335.6% during the fourth quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company’s stock valued at $107,727,000 after purchasing an additional 1,996,003 shares during the last quarter. SHANDA ASSET MANAGEMENT HOLDINGS Ltd acquired a new stake in Moderna in the first quarter worth about $28,350,000. Jacobs Levy Equity Management Inc. acquired a new stake in Moderna in the first quarter worth about $28,308,000. Jump Financial LLC lifted its holdings in Moderna by 5,590.0% in the first quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock worth $25,584,000 after purchasing an additional 886,567 shares during the period. Finally, Invesco Ltd. lifted its holdings in Moderna by 17.5% in the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock valued at $166,801,000 after acquiring an additional 877,162 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

NASDAQ:MRNA opened at $24.84 on Wednesday. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $75.37. The stock’s 50 day moving average price is $28.07 and its 200 day moving average price is $28.08. The company has a market capitalization of $9.66 billion, a P/E ratio of -3.30 and a beta of 1.93.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. During the same quarter last year, the company posted ($3.33) earnings per share. The company’s revenue for the quarter was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on MRNA. Evercore ISI set a $32.00 price target on shares of Moderna in a report on Friday, August 1st. Leerink Partners reduced their price objective on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a research note on Friday, August 22nd. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Moderna in a research note on Sunday, July 13th. Bank of America reduced their price objective on shares of Moderna from $26.00 to $25.00 and set an “underperform” rating for the company in a research note on Tuesday, July 22nd. Finally, JPMorgan Chase & Co. set a $26.00 price objective on shares of Moderna in a research note on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have given a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus price target of $41.81.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.